Literature DB >> 30483827

Diltiazem used as a tacrolimus-sparing agent for treatment of pediatric patients with refractory nephrotic syndrome: a case report and retrospective analysis.

Jie-Yu Sun1,2, Ya-Hui Hu1, Hong-Li Guo1, Xia Jing1, Ze-Jun Xu1, Fang Sun1, Hui-Lei Guo1, Xuan-Sheng Ding2, Feng Chen3, Jing Xu4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30483827     DOI: 10.1007/s00228-018-2604-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  1 in total

1.  Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms.

Authors:  Junyan Wang; Lingfei Huang; Peng Gao; Yan Hu; Yinghua Ni; Zhengyi Zhu; Liwen Zhang; Jufei Yang; Huifen Zhang; Luo Fang
Journal:  Eur J Clin Pharmacol       Date:  2020-08-15       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.